In line with this, recent phase II data in HS patients who had previously failed anti-TNF therapy demonstrated a promising clinical response to lutikizumab (HiSCR 48.7%–59.5%, placebo 35%; ref. 31), a monoclonal antibody and dual-variable-domain IL-1α/1β antagonist. Here, TNF is linked to histiocytic sarcoma.